Lack of antidiuretic activity of lanreotide in the diabetes insipidus rat.

J Pharmacol Exp Ther

Department of Pharmacology, New York Medical College, Valhalla, USA.

Published: March 1996

Lanreotide is a somatostatin analog which possesses antidiuretic activity in the rat. To determine whether vasopressin participates in the antidiuretic response to lanreotide, experiments were performed with diabetes insipidus (DI) rates homozygous for vasopressin deficiency. Lanreotide significantly increased urine osmolality and decreased urine volume and free water clearance during the 2-h period after injecting 400 microgram/kg s.c. in 12 awake Wistar-Kyoto rats that were undergoing water diuresis. Although lanreotide decreased serum growth hormone levels (24.2 +/- 6.1 vs. 0.9 +/- 0.1 ng/ml, P < .01), administration of recombinant human growth hormone (1 mg/kg s.c.) did not affect the renal response. Lanreotide (200 microgram/kg s.c.) also significantly increased urine osmolality and free water reabsorption and tended to decrease urine volume in 15 water-loaded Long-Evans rats. In contrast, lanreotide (200 or 400 microgram/kg s.c.) did not affect urine osmolality, urine volume or free water clearance when administered acutely or chronically to DI rats. These results suggest that vasopressin plays a role in the renal response to lanreotide in the rat

Download full-text PDF

Source

Publication Analysis

Top Keywords

response lanreotide
12
urine osmolality
12
urine volume
12
free water
12
antidiuretic activity
8
lanreotide
8
diabetes insipidus
8
increased urine
8
volume free
8
water clearance
8

Similar Publications

Introduction: First-generation somatostatin receptor ligands (fg-SRLs) are the cornerstone of acromegaly treatment. Additional benefits were shown using high dose (HD) or high frequency (HF), relatively short-term regimens. Although several predictors of response to standard dose (SD)-fg-SRLs were reported, outcome biomarkers for HF administration are not yet available.

View Article and Find Full Text PDF

Hypertrophic osteoarthropathy (HOA: MIM 167100)) is classified into primary and secondary types. Primary HOA, also known as pachydermoperiostosis (PDP), is a rare genetic condition with distinct clinical features including digital clubbing, skin thickening, and periostosis. Secondary HOA often occurs as a paraneoplastic syndrome or is associated with systemic diseases.

View Article and Find Full Text PDF

Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group.

Rev Endocr Metab Disord

December 2024

Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sapienza University of Rome, Rome, Italy.

Neuroendocrine neoplasms (NENs) originating in the gastroenteropancreatic (GEP) tract are rare tumors often associated with significant metabolic disturbances and nutritional challenges. This review explores the intricate relationship between nutritional status and the development, progression, and prognosis of GEP-NENs. Through an extensive literature search encompassing studies up to April 2024, we examined various factors, including obesity, malnutrition, metabolic syndrome and type 2 diabetes mellitus, and their roles in the development and progression of GEP-NENs.

View Article and Find Full Text PDF

Background: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials.

Patients And Methods: In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.

View Article and Find Full Text PDF

A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration.

Int J Pharm

December 2024

Department of Medicinal Chemistry, Uppsala University, BMC P.O. Box 574, SE-751 23, Uppsala, Sweden. Electronic address:

For many biopharmaceuticals, subcutaneous (sc) administration is the only viable route. However, there is no in vitro method available accurately predicting the absorption profiles of subcutaneously injected pharmaceuticals. In this work, we show that a recently developed microfluidics method for interaction studies (MIS) has the potential to be useful in this respect.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!